Imprida

RSS

amlodipine / valsartan

Withdrawn
This medicine is now withdrawn from use in the European Union.

Overview

The marketing authorisation for Imprida has been withdrawn at the request of the marketing authorisation holder.

This EPAR was last updated on 11/05/2017

Authorisation details

Product details
Name
Imprida
Agency product number
EMEA/H/C/000775
Active substance
  • valsartan
  • amlodipine (as amlodipine besilate)
International non-proprietary name (INN) or common name
  • amlodipine
  • valsartan
Therapeutic area (MeSH)
Hypertension
Anatomical therapeutic chemical (ATC) code
C09DB01
Publication details
Marketing-authorisation holder
Novartis Europharm Ltd
Revision
20
Date of issue of marketing authorisation valid throughout the European Union
17/01/2007
Contact address
Frimley Business Park
Camberley GU16 7SR
United Kingdom

Product information

03/04/2017 Imprida - EMEA/H/C/000775 - WS/0709

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Agents acting on the renin-angiotensin system

Therapeutic indication

Treatment of essential hypertension.

Imprida is indicated in patients whose blood pressure is not adequately controlled on amlodipine or valsartan monotherapy.

Assessment history

Changes since initial authorisation of medicine

How useful was this page?

Add your rating